Understanding and regulating autoimmune disease through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) family transcription factor, v-rel reticuloendotheliosis viral oncogene homolog B (RelB).

通过活化 B 细胞核因子 kappa-轻链增强子 (NF-kappaB) 家族转录因子 v-rel 网状内皮增生病毒癌基因同源物 B (RelB) 了解和调节自身免疫性疾病。

• 批准号: FT0991552
• 负责人: Prof Ranjeny Thomas
• 金额: $ 63.57万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-11-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT0991552
• 关键词: Understanding; regulating; autoimmune; disease; through

This program is well-aligned with the national research priority: Promoting and Maintaining Good Health. The disabling conditions rheumatoid arthritis and type 1 diabetes affect over 1% of Australia's population. They are incurable, so disability and the need for treatment persist into old age and life expectancy is reduced. The program focuses on more effective and safer treatment, and future disease prevention, with immune therapy. This will have social and economic benefits to Australia. The research will advance Australia's intellectual leadership in Immunology, providing research training and career opportunities, and will lead to strong collaborations between basic scientists, clinicians and industry.

该计划与国家研究重点：促进和保持良好健康完全一致。类风湿性关节炎和 1 型糖尿病影响着超过 1% 的澳大利亚人口。它们无法治愈，因此残疾和治疗需求会持续到老年，预期寿命也会缩短。该计划的重点是通过免疫疗法进行更有效、更安全的治疗以及未来的疾病预防。这将为澳大利亚带来社会和经济效益。该研究将提升澳大利亚在免疫学领域的智力领导地位，提供研究培训和职业机会，并将促进基础科学家、临床医生和工业界之间的强有力合作。